BeOne Medicines Heads Into Earnings With Bulls Firmly in Charge

ONC reports today with the analyst community broadly constructive, the stock up 15% over the past month, and positioning that reads more relaxed than charged.

The options market shows no sign of pre-earnings anxiety. The put/call ratio is running at 0.73, almost exactly in line with its 20-day average of 0.73 — a z-score near zero, meaning options traders are neither piling into protection nor making aggressive directional bets. That neutrality fits the broader lending picture: availability is extremely loose at over 3,500% of short interest, meaning the pool of shares available to borrow dwarfs the actual short position by a wide margin. Short interest itself is a modest 0.84% of the free float, with borrowing costs barely above half a percent. There is no meaningful bearish pressure in the lending market heading into the print.

The bull case heading into today rests on Brukinsa's commercial trajectory. The drug is projected to reach peak sales of roughly $7.1 billion by 2034, and multiple analysts lifted price targets after the last earnings release in early August, when the stock gained 2% on the day and then rallied more than 11% over the following five sessions. TD Cowen raised its target to $454 and the broader analyst consensus now prices in roughly 15% upside from the current $376 level, with a mean target near $431. JP Morgan raised its target to $425 in late July, reinforcing that bellwether support remains intact. The bear case centres on clinical and geopolitical risk: a highly competitive oncology market, significant pipeline cash burn, and the geopolitical uncertainty inherent in a China-linked business. EPS momentum ranks in the 86th percentile, and EPS surprise history places the company near the 78th percentile — a strong earnings execution track record that underpins the optimistic consensus.

One ownership detail warrants attention. Founder and CEO John Oyler sold approximately $30 million worth of shares on August 11 and 12, just two weeks before today's report. The transactions appear to follow a programmatic pattern across multiple tranches and prices, rather than a single large block sale, but the timing and aggregate size are notable. Hillhouse Investment Management trimmed its position by over one million shares as of June 30, reducing a previously significant stake. Against that, Capital Research added 678,000 shares through July, and Citadel built a new position of roughly 393,000 shares last quarter — suggesting institutional demand is not one-directional.

The print will therefore test whether Brukinsa's revenue trajectory in the most recent quarter supports the kind of peak-sales extrapolation that has driven the stock to near its 52-week high — and whether management's forward guidance addresses the clinical pipeline and cash deployment questions that remain the central bear argument.